May 2011. EPiQ Life Science AB awarded €357 000 through Vinnova Forska&Väx

EPiQ Life Science AB has been awarded 3,2 million Swedish Kronor, approximately €357 000, through the Vinnova program Forska&Väx for continued development of AFRtracker, a product that assists in the decision making for patients diagnosed with atrial fibrillation.
The technology in AFRtracker has been developed in co-operation with Cardiolund Research AB and has been through clinical studies in five countries during 2010 with good results.